Zinc finger protein ZBTB20 expression is increased in hepatocellular carcinoma and associated with poor prognosis

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Wang, Qing ^a   Tan, Ye Xiong ^a   Ren, Yi Bin ^a   Dong, Li Wei ^a   Xie, Zhi Fang ^a   Tang, Liang ^a   Cao, Dan ^a   Zhang, Wei Ping ^a   Hu, He Ping ^a   Wang, Hong yang ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; PROTEIN ZBTB20; RNA 18S; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN; NERVE PROTEIN; RNA; TRANSCRIPTION FACTOR; TUMOR PROTEIN; ZBTB20 PROTEIN, HUMAN;

ADULT; ARTICLE; CANCER CELL CULTURE; CANCER INVASION; CANCER TISSUE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER PARENCHYMA; LIVER RESECTION; MALE; METASTASIS; OVERALL SURVIVAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RECURRENCE RISK; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; AGED; BIOSYNTHESIS; CHINA; COMORBIDITY; EPIDEMIOLOGY; FOLLOW UP; GENE EXPRESSION REGULATION; GENETICS; HEPATITIS B; HEPATITIS C; LIVER; LIVER TUMOR; METABOLISM; MIDDLE AGED; MORTALITY; RECURRENT DISEASE;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; CHINA; COMORBIDITY; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; LIVER; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NERVE TISSUE PROTEINS; PROGNOSIS; RECURRENCE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; SAMPLING STUDIES; TRANSCRIPTION FACTORS;

EID: 79959445345     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-271     Document Type: Article

References (43)

1. Max Parkin D, Freddie B, Ferlay J, Paola P. Global Cancer Statistics, 2002. CA Cancer J Clin 2005, 55:74-108. 10.3322/canjclin.55.2.74, 15761078.
2. El-Serag HB, Klenhard R. Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis. Gastroenterology 2007, 132:2557-2576. 10.1053/j.gastro.2007.04.061, 17570226.
3. Albagli O, Dhordain P, Deweindt C, Lecocq G, Leprince D. The BTB/POZ domain: a new protein-protein interaction motif common to DNA-and actin-binding proteins. Cell Growth Differ 1995, 6(9):1193-1198.
4. Kelly KF, Daniel JM. POZ for effect - POZ-ZF transcription factors in cancer and development. Trends Cell Biol 2006, 16(11):578-587. 10.1016/j.tcb.2006.09.003, 16996269.
5. Stogios PJ, Downs GS, Jauhal JJ, Nandra SK, Privé GG. Sequence and structural analysis of BTB domain proteins. Genome Biol 2005, 6:R82. 10.1186/gb-2005-6-10-r82, 1257465, 16207353.
6. Polo JM, Dell'Oso T, Ranuncolo SM, Cerchietti L, Beck D, Da silva GF, Prive Gibert G, Licht JD, Melnick A. Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells. Nat Med 2004, 10:1329-1335. 10.1038/nm1134, 15531890.
7. Phan RT, Dalla-Favera R. The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells. Nature 2004, 432:635-639. 10.1038/nature03147, 15577913.
8. Margalit O, Amram H, Amariglio N, Simon AJ, Shaklai S, Granot G, Minsky N, Shimoni A, Harmelin A, Givol D, Shohat M, Oren M, Rechavi G. BCL6 is regulated by p53 through a response element frequently disrupted in B-cell non-Hodgkin lymphoma. Blood 2006, 107:1599-1607. 10.1182/blood-2005-04-1629, 16249378.
9. Ranuncolo SM, Polo JM, Dierov J, singer M, Kuo T, Greally J, Green R, Carroll M, Melnick A. Bcl-6 mediates the germinal center B cell phenotype and lymphomagenesis through transcriptional repression of the DNA-damage sensor ATR. Nat Immunol 2007, 8:705-714. 10.1038/ni1478, 17558410.
10. Yeyati PL, Shaknovich R, Boterashvili S, Li J, Ball HJ, Waxman S, Burchenal KN, Dmitrovsky ED, Zelent A, Licht JD. Leukemia translocation protein PLZF inhibits cell growth and expression of cyclin A. Oncogene 1999, 18:925-934. 10.1038/sj.onc.1202375, 10023668.
11. Costoya JA, Pandolfi PP. The role of promyelocytic leukemia zinc finger and promyelocytic leukemia in leukemogenesis and development. Curr Opin Hematol 2001, 8:212-217. 10.1097/00062752-200107000-00006, 11561158.
12. Felicetti F, Errico MC, Bottero L, Segnalini P, Stoppacciaro A, Biffoni M, Felli N, Mattia G, Petrini M, Colombo MP, Peschle C, Care A. The promyelocytic leukemia zinc finger-microRNA-221/-222 pathway controls melanoma progression through multiple oncogenic mechanisms. Cancer Res 2008, 68:2745-2754. 10.1158/0008-5472.CAN-07-2538, 18417445.
13. Shiraishi K, Yamasaki K, Nanba D, Inoue H, Hanakawa Y, Shirakata Y, Hashimoto K, Higashiyama S. Pre-B-cell leukemia transcription factor 1 is a major target of promyelocytic leukemia zinc-finger-mediated melanoma cell growth suppression. Oncogene 2007, 26:339-348. 10.1038/sj.onc.1209800, 16862184.
14. Parrado A, Robledo M, Moya-Quiles MR, Marin LA, Chomienne C, Padua RA, Alvarez-lopez MR. The promyelocytic leukemia zinc finger protein down-regulates apoptosis and expression of the proapoptotic BID protein in lymphocytes. Proc Natl Acad Sci USA 2004, 101:1898-1903. 10.1073/pnas.0308358100, 357024, 14769944.
15. Maeda T, Hobbs RM, Merghoub T, Merghoub T, Guernah I, Zelent A, Cordon-cardo C, Teruya-Feldstein, Pandolfi PP. Role of the proto-oncogene Pokemon in cellular transformation and ARF repression. Nature 2005, 433:278-285. 10.1038/nature03203, 15662416.
16. Maeda T, Hobbs RM, Pandolfi PP. The transcription factor Pokemon: a new key player in cancer pathogenesis. Cancer Res 2005, 65:8575-8578. 10.1158/0008-5472.CAN-05-1055, 16204018.
17. Aggarwal A, Hunter WJ, Aggarwal H, Silva ED, Davey MS, Murphy RF, Agrawal DK. Expression of leukemia/lymphoma-related factor (LRF/POKEMON) in human breast carcinoma and other cancers. Exp Mol Pathol 2010, 89(2):140-8. Epub 2010 May 21, 10.1016/j.yexmp.2010.05.002, 20471975.
18. Maeda T, Merghoub T, Hobbs RM, Dong L, Maeda M, Zakrzewski J, R Brink MRM, Zelent A, Shigematsu H, Akashi K, Teruya-Feldstein J, Cattoretti G, pandolfi PP. Regulation of B versus T lymphoid lineage fate decision by the proto-oncogene LRF. Science 2007, 316:860-866. 10.1126/science.1140881, 2978506, 17495164.
19. Mondal AM, Chinnadurai S, Datta K, Chauhan SS, Sinha S, Chattopadhyay P. Identification and functional characterization of a novel unspliced transcript variant of HIC-1 in human cancer cells exposed to adverse growth conditions. Cancer Res 2006, 66:10466-10477. 10.1158/0008-5472.CAN-06-0352, 17079468.
20. Waha A, Waha A, Koch A, Meyer-Puttlitz B, Weqqen S, Sorensen N, Tonn JC, Albrecht S, Goodyer CG, Wiestler OD, Pietsch T. Epigenetic silencing of the HIC-1 gene in human medulloblastomas. J Neuropathol Exp Neurol 2003, 62:1192-1201.
21. Nishida N, Nagasaka T, Nishimura T, Ikai I, Boland CR, Goel A. Aberrant methylation of multiple tumor suppressor genes in aging liver, chronic hepatitis, and hepatocellular carcinoma. Hepatology 2008, 47:908-918. 2865182, 18161048.
22. Hayashi M, Tokuchi Y, Hashimoto T, Hayashi S, Nishida K, Ishikawa Y, Nakagawa K, Tsuchiya S, Tsuchiya E. Reduced HIC-1 gene expression in non-small cell lung cancer and its clinical significance. Anticancer Res 2001, 21:535-540.
23. Nicoll G, Crichton DN, McDowell HE, Kernohan N, Hupp TR, Thompson AM. Expression of the Hypermethylated in Cancer gene (HIC-1) is associated with good outcome in human breast cancer. Br J Cancer 2001, 85:1878-1882. 10.1054/bjoc.2001.2163, 2363999, 11747329.
24. Mackler SA, Korutla L, Cha XY, Koebbe MJ, Fournier KM, Bowers MS, Kalivas PW. NAC-1 is a brain POZ/BTB protein that can prevent cocaine-induced sensitization in the rat. J Neurosci 2000, 20:6210-6217.
25. Korutla L, Neustadter JH, Fournier KM, Mackler SA. NAC1, a POZ/BTB protein present in the adult mammalian brain, triggers apoptosis after adenovirus-mediated overexpression in PC-12 cells. Neurosci Res 2003, 46:33-39. 10.1016/S0168-0102(03)00024-5, 12725910.
26. Nakayama K, Nakayama N, Davidson B, Sheu JJ, Jinawath N, Santillan A, Salani R, Bristow RE, Morin PJ, Kurman RJM, Wang TL, Shih L. A BTB/POZ protein, NAC-1, is related to tumor recurrence and is essential for tumor growth and survival. Proc Natl Acad Sci USA 2006, 103:18739-18744. 10.1073/pnas.0604083103, 1693732, 17130457.
27. Yeasmin S, Nakayama K, Ishibashi M, Claes G. Trope, Tian-li Wang, leming Shih: Expression of the bric-a-brac tramtrack broad complex protein NAC-1 in cervical carcinomas seems to correlate with poorer prognosis. Clin Cancer Res 2008, 14:1686-1691. 10.1158/1078-0432.CCR-07-4085, 18347169.
28. Davidson B, Berner A, Trope' CG, Wang TL, Shih I. Expression and clinical role of the bric-a-brac tramtrack broad complex/poxvirus and zinc protein NAC-1 in ovarian carcinoma effusions. Hum Pathol 2007, 38:1030-1036. 10.1016/j.humpath.2006.12.009, 17391728.
29. Nakayama K, Nakayama N, Wang TL, Shih I. NAC-1 controls cell growth and survival by repressing transcription of Gadd45GIP1, a candidate tumor suppressor. Cancer Res 2007, 67:8058-64. 10.1158/0008-5472.CAN-07-1357, 17804717.
30. Prokhortchouk A, Sansom O, Selfridge J, Caballero IM, Salozhin S, Aithozhina D, Cerchietti L, Meng FG, Augenlicht LH, Mariadason JM, Hendrich B, Melnick A, Prokhortchouk E, Clarke A, Bird A. Kaiso-deficient mice show resistance to intestinal cancer. Mol Cell Biol 2006, 26:199-208. 10.1128/MCB.26.1.199-208.2006, 1317619, 16354691.
31. Van Roy FM, McCrea PD. A role for Kaiso-p120ctn complexes in cancer?. Nat Rev Cancer 2005, 5:956-964. 10.1038/nrc1752, 16294216.
32. Daniel JM, Reynolds AB. The catenin p120 (ctn) interacts with Kaiso, a novel BTB/POZ domain zinc finger transcription factor. Mol Cell Biol 1999, 19:3614-3623. 84161, 10207085.
33. Soubry A, van Hengel J, Parthoens E, Colpaert C, Van Marck E, Waltrgny D, Reynolds AB, van Roy F. Expression and nuclear location of the transcriptional repressor Kaiso is regulated by the tumor microenvironment. Cancer Res 2005, 65:2224-2233. 10.1158/0008-5472.CAN-04-2020, 15781635.
34. Zhang W, Mi J, Li N, Sui L, Wan T, Zhang J, Chen T, Cao X. Identification and Characterization of ZBTB20, a Novel Human BTB/POZ Zinc Finger Protein Sharing Homology to BCL-6. Biochem Biophys Res Commun 2001, 282:1067-1073. 10.1006/bbrc.2001.4689, 11352661.
35. Mitchelmore C, Kjaerulff KM, Pedersen HC, Nielsen JV, Rasmussen TE, Fisker MF, Finsen B, Pedersen KM, Jensen NA. Characterization of Two Novel Nuclear BTB/POZ Domain Zinc Finger Isoforms. J Biol Chem 2002, 277:7598-7609. 10.1074/jbc.M110023200, 11744704.
36. Harboe TL, Tümer Z, Hansen C, Jensen NA, Tommerup N. Assignment of the human zinc finger gene, ZNF288, to chromosome 3 band q13.2 by radiation hybrid mapping and fluorescence in situ hybridisation. Cytogenet Cell Genet 2000, 89:156-157. 10.1159/000015600, 10965110.
37. Nielsen JV, Nielsen FH, Ismail R, Noraberg J, Jensen NA. Hippocampus-like corticoneurogenesis induced by two isoforms of the BTB-zinc finger gene Zbtb20 in mice. Development 2007, 134:1133-1140. 10.1242/dev.000265, 17301088.
38. Xie Z, Zhang H, Tsai W, Zhang Y, Du Y, Zhong J, Szpirer C, Zhu M, Cao X, Barton MC, Grusby MJ, Zhang WJ. Zinc finger protein ZBTB20 is a key repressor of alpha-fetoprotein gene transcription in liver. Proc Natl Acad Sci USA 2008, 105:10859-10864. 10.1073/pnas.0800647105, 2504784, 18669658.
39. Sutherland AP, Zhang H, Zhang Y, Michaud M, Xie Z, Patti ME, Grusby MJ, Zhang WJ. Zinc finger protein Zbtb20 is essential for postnatal survival and glucose homeostasis. Mol Cell Biol 2009, 29:2804-2815. 10.1128/MCB.01667-08, 2682054, 19273596.
40. Sobin LH, Gospodarowicz MK, Wittekind CH, . Eds TNM Classification of Malignant Tumors. 2002, 81-83. New York, Wiley-Liss, Inc., 6, Eds.
41. Dong LW, Kong XN, Yan HX, Yu LX, Chen L, Yang W, Liu Q, Huang DD, Wu MC, Wang HY. Signal regulatory protein alpha negatively regulates both TLR3 and cytoplasmic pathways in type I interferon induction. Mol Immunol 2008, 45:3025-3035. 10.1016/j.molimm.2008.03.012, 18471880.
42. Poon RT, Fan ST, Ng IO, Lo CM, Liu CL, Wong J. Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer 2000, 89:500-507. 10.1002/1097-0142(20000801)89:3<500::AID-CNCR4>3.0.CO;2-O, 10931448.
43. Cerchietti LC, Lopes EC, Yang SN, Hatzi K, Bunting KL, Tsikitas LA, Mallik A, Robles AI, Walling J, Varticovski L, Shaknovich R, Bhalla KN, Chiosis G, Melnick A. A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas. Nat Med 2009, 15:1369-1376. 10.1038/nm.2059, 2805915, 19966776.